您的购物车当前为空
PDE4-IN-13 is a phosphodiesterase 4 inhibitor with an IC50 value of 1.56 μM, exhibiting anti-inflammatory and antioxidative properties. It is utilized in the study of chronic obstructive pulmonary disease (COPD).
PDE4-IN-13 is a phosphodiesterase 4 inhibitor with an IC50 value of 1.56 μM, exhibiting anti-inflammatory and antioxidative properties. It is utilized in the study of chronic obstructive pulmonary disease (COPD).
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 mg | 待询 | 待询 | |
| 50 mg | 待询 | 待询 |
| 产品描述 | PDE4-IN-13 is a phosphodiesterase 4 (PDE4) inhibitor exhibiting anti-inflammatory and antioxidant activities, with an half maximal inhibitory concentration (IC50) value of 1.56 μM. It is used in the research of chronic obstructive pulmonary disease (COPD) [1]. |
| 靶点活性 | PDE4:1.56 μM |
| 体外活性 | PDE4-IN-13(化合物6o)能显著抑制RAW264.7巨噬细胞内由LPS诱导的TNF-α产出,并降低小鼠肺组织匀浆中Fe 2+诱发的MDA生成。此外,PDE4-IN-13在还原Fe 3+以及络合Fe 2+方面也表现出卓越的效果[1]。 |
| 体内活性 | PDE4-IN-13(化合物 6o)以50 mg/kg和100 mg/kg剂量腹膜内注射,能显著抑制LPS引发的小鼠血清中TNF-α的升高[1]。 |
| 分子量 | 340.37 |
| 分子式 | C20H20O5 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多